###begin article-title 0
The Heme Oxygenase-1 Genotype is a Risk Factor to Renal Impairment of IgA Nephropathy at Diagnosis, Which is a Strong Predictor of Mortality
###end article-title 0
###begin p 1
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sup>
1Members are listed in Appendix.
###end p 1
###begin p 2
###xml 499 500 499 500 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1076 1077 1076 1077 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 356 364 <span type="species:ncbi:9606">patients</span>
###xml 1265 1273 <span type="species:ncbi:9606">patients</span>
The induction of heme oxygenase-1 (HO-1) ameliorates oxidative stress and inflammatory process, which play important roles in IgA nephropathy. We hypothesized length polymorphism in the promoter region of the HO-1 gene, which is related to the level of gene transcription, is associated with disease severity of IgA nephropathy. The subjects comprised 916 patients with IgA nephropathy and gene data. Renal impairment was defined as an estimated glomerular filtration rate less than 60 mL/min/1.73 m2 at diagnosis. The short (S: <23), medium (M: 23-28), and long (L: >28) (GT) repeats in the HO-1 gene was determined. The frequencies of S/S, S/M, M/M, S/L, L/M, and L/L genotypes were 7.2%, 6.9%, 3.1%, 30.8%, 22.7%, and 29.4%, respectively. The baseline characteristics were not different. In the S/S genotypic group, the renal impairment rate was 18.2%, which was lower than 32.2% in the group with M/M, L/M, or L/L genotype. The odds ratio of renal impairment in S/S genotype, compared to that in M/M, L/M, or L/L genotype, was 0.216 (95% confidence interval, 0.060-0.774, p=0.019). The HO-1 gene promoter length polymorphism was related to the renal impairment of IgA nephropathy at diagnosis, which is an important risk factor for mortality in IgA nephropathy patients.
###end p 2
###begin title 3
INTRODUCTION
###end title 3
###begin p 4
###xml 195 196 195 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 456 457 456 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 532 533 532 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 534 535 534 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 562 563 562 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 610 611 610 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 637 638 637 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 640 642 640 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 704 706 704 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
Heme oxygenase (HO) is the rate-limiting enzyme for the breakdown of heme to generate carbon monoxide, iron, and biliverdin. Biliverdin is rapidly converted to bilirubin by biliverdin reductase (1). The induction of HO-1, the inducible isoform of HO, is an important endogenous mechanism for cytoprotection and mediates the beneficial effects of HO, such as antioxidant, anti-inflammatory, anti-proliferative, anti-apoptotic, and immunomodulatory effects (1). These effects may be mediated through the products of heme degradation (2-6) and regulation of MCP-1 (7), p38 mitogen activated protein (MAP) kinase (8), cell-cycle regulators (9, 10), and T-cell- and natural killer cell-mediated cytotoxicity (11).
###end p 4
###begin p 5
###xml 211 213 211 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 245 247 245 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 249 251 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 267 269 267 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 292 294 292 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 329 331 329 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 570 572 570 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 334 339 <span type="species:ncbi:9606">Human</span>
###xml 340 348 <span type="species:ncbi:9606">patients</span>
Experimental and clinical evidences support the important protective role of HO-1 in several renal diseases. Induction of HO-1 is an adaptive and beneficial response to renal injury secondary to rhabdomyolysis (12), ischemia-reperfusion injury (13, 14), nephrotoxin (15), glomerulonephritis (16), and renal transplant rejection (17). Human patients with HO-1 deficiency showed iron deposition in the proximal tubule and pathologic change in the kidney, as well as growth retardation, anemia, leukocytosis, lymphadenopathy, and increased sensitivity to oxidative injury (18).
###end p 5
###begin p 6
###xml 126 128 126 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 129 131 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 194 195 194 195 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 196 197 196 197 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 225 227 225 227 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">16</sub>
###xml 235 237 235 237 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">20</sub>
###xml 265 267 265 267 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">29</sub>
###xml 275 277 275 277 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">38</sub>
###xml 279 281 279 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 359 361 359 361 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">22</sub>
###xml 441 443 441 443 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">26</sub>
###xml 452 454 452 454 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">30</sub>
###xml 470 472 470 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 595 597 595 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 599 601 599 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 637 639 637 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 655 657 655 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 693 695 693 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 697 699 697 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 792 794 792 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 59 64 <span type="species:ncbi:9606">human</span>
A (GT)n repeat region located between -198 and -258 of the human HO-1 gene promoter is associated with up-regulation of HO-1 (19-21). The promoter activity of the HO-1 gene was up-regulated by H2O2 exposure in genes with (GT)16 or (GT)20, but not in genes with (GT)29 or (GT)38 (19). The reporter gene expression driven by the HO-1 gene promoter carrying (GT)22 was about four- and eight-fold higher than that directed by promoters with (GT)26 and (GT)30, respectively (20). Length polymorphism of this region correlates with susceptibility in several diseases, such as coronary artery disease (20, 22), ischemic cerebrovascular events (19), lung cancer (23), and renal allograft dysfunction (17, 24), although, in some reports, length polymorphism is not associated with disease conditions (25).
###end p 6
###begin p 7
###xml 91 93 91 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 177 179 177 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 181 183 181 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 296 298 296 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 415 417 415 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 225 233 <span type="species:ncbi:9606">patients</span>
In IgA nephropathy, which is the most common type of primary glomerulonephritis worldwide (26), oxidative stress plays a role in the development and progression of nephropathy (27, 28). HO-1 immunoreactivity in the kidney of patients with IgA nephropathy was increased compared that in controls (27). The advanced oxidation protein products were the independent risk factor to renal progression of IgA nephropathy (27). We hypothesized that length polymorphism in the HO-1 gene promoter region will be associated with disease severity of IgA nephropathy at diagnosis.
###end p 7
###begin title 8
MATERIALS AND METHODS
###end title 8
###begin title 9
Study subjects
###end title 9
###begin p 10
###xml 814 816 814 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 160 168 <span type="species:ncbi:9606">patients</span>
###xml 502 510 <span type="species:ncbi:9606">patients</span>
###xml 617 625 <span type="species:ncbi:9606">patients</span>
###xml 897 905 <span type="species:ncbi:9606">patients</span>
This study was approved by the Institutional Review Boards at the participating hospitals before the data were gathered. Informed consent was obtained from all patients. The subjects were enrolled in the Progressive REnal disease and Medical Informatics and gEnomics Research (PREMIER) study which was sponsored by the Korean Society of Nephrology. In the PREMIER study, 34 hospitals and clinics in Korea participated and shared the clinical data and genomic DNA extracted from the peripheral blood of patients with primary and secondary glomerulonephritis diagnosed by renal biopsy in each institute. There were 968 patients aged 18 yr or more with IgA nephropathy, which was diagnosed by the pathologic findings of prominent deposition of IgA antibodies in the mesangium detected by immunofluorescence staining (26), and who agreed to collect DNA sample, from May 1986 to April 2007. Of the 968 patients, the serum creatinine values at the time of renal biopsy were available for 916 subjects.
###end p 10
###begin title 11
Clinical data
###end title 11
###begin p 12
###xml 1234 1236 1234 1236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 1335 1336 1335 1336 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 57 65 <span type="species:ncbi:9606">patients</span>
The participating researchers had selected the candidate patients and one qualified nurse, who visited every participated institution, input the clinical data into the formatted database on the website () at the time of renal biopsy and during follow-up visits. During the follow-up period, we gathered the data on age, gender, body weight, height, smoking habit, history of diabetes mellitus, current hypertension, blood pressure, total bilirubin, alanine aminotransaminase, aspartate aminotransferase, serum uric acid, serum protein, serum albumin, serum cholesterol, hemoglobin, serum creatinine, proteinuria by dipstick test, urine RBC measured by microscopic examination of urine, medication of angiotensin-converting enzyme inhibitors, angiotensin II type I receptor blockers, other hypertensive agents, any kind of steroid and HMG-CoA reductase inhibitors. Current hypertension was defined as systolic blood pressure of 140 mmHg or more, diastolic blood pressure of 90 mmHg or more, or taking anti-hypertensive medication. Smoking habit was categorized as current smoker or current non-smoker. We calculated the estimated glomerular filtration rate (eGFR) by the modified modification of diet in renal disease (MDRD) equation (29). The renal impairment of IgA nephropathy at biopsy was defined as eGFR less than 60 mL/min/1.73 m2.
###end p 12
###begin p 13
###xml 309 317 <span type="species:ncbi:9606">patients</span>
###xml 361 369 <span type="species:ncbi:9606">patients</span>
The mortality and primary cause of death were obtained from the database of the Korean National Statistical Office (). The mortality data until December 2006 available on this database were searched based on the unique identifier. All study subjects were searched in the national mortality database except 26 patients who were enrolled after January 2007 and 5 patients whose identifiers were not matched to the data of the Korean National Statistical Office. The primary cause of mortality was provided as a 4-digit, ICD-10 code, which was recorded by the physicians. There were 11 deaths during a median follow-up period of 22.0 months (range 0.1-247 months).
###end p 13
###begin title 14
HO-1 genotype assessment
###end title 14
###begin p 15
###xml 284 286 284 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 562 564 562 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 1068 1070 1056 1058 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 1072 1074 1060 1062 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
Genomic DNA was isolated from whole blood samples using the a QIAamp blood kit (Qiagen, Valencia, CA, U.S.A.) according to the manufacturer's protocol. Polymerase chain reaction (PCR) amplifications of the HO-1 (GT)n repeat length polymorphism were performed as described previously (30). The HO-1 gene 5'-flanking region containing a poly (GT) n repeat was amplified by PCR with a 6-FAM-labeled sense primer (5'-AGAGCCTGCAGCTTCTCAGA-3') and an unlabeled antisense primer (5'-ACAAAGTCTCCGGATAGGAC-3'), which were designed on the basis of the published sequence (31). Thirty PCR cycles of 94℃ for 30 sec, 57℃ for 30 sec and 72℃ for 30 sec were conducted. For fragment analysis, 1 microL of the PCR product was mixed with 9 microL of HiDi-Formamide (Applied Biosystems, Foster City, CA, U.S.A.) and 0.5 microL of the Genscan 500 LIZ size standard (Applied Biosystems) in 384-well plates. After a denaturation and cooling step, the fragments were analyzed on the ABI 3730XL sequencing system (Applied Biosystems). Each repeat number was calculated with 2 cloned alleles (20, 22) as size markers. For data analysis, we applied GeneMapper version 3.7 software (Applied Biosystems).
###end p 15
###begin title 16
Statistical analysis
###end title 16
###begin p 17
###xml 957 958 957 958 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
The SPSS (SPSS version 12.0, Chicago, IL, U.S.A.) package was used for statistical analysis. Differences in proportions among the subject groups were compared by chi-square test. Group differences for continuous variables were assessed by the Student t-test or one-way ANOVA test according to the number of groups. To determine whether the genotype group was associated independently with the renal impairment of IgA nephropathy at the time of renal biopsy, we used multiple logistic regression analysis, adjusted for age, gender, and univariate risk factors, for the renal impairment. We repeated the analyses after stratification by gender, age, hypertension, and proteinuria 3+ or more by dipstick test, which are well-known risk factors of renal impairment. We compared the cumulative incidence of mortality by log-rank test. We used Cox's hazard proportional model to determine the relationship between the HO-1 genotype group and mortality. Two-sided p values are reported, with the level of statistical significance set at 0.05. All data are shown as mean+/-standard deviation or frequency per observation.
###end p 17
###begin title 18
RESULTS
###end title 18
###begin title 19
Allele frequencies at the polymorphic locus
###end title 19
###begin p 20
###xml 154 160 154 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 273 275 273 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 277 279 277 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
The number of (GT)n repeats ranged from 14-42 and exhibited a bimodal distribution with one peak located at 22 GT repeats and the other at 29 GT repeats (Fig. 1). Because the inducibility of the HO-1 gene promoter was positively correlated with the number of (GT) repeats (19, 20), we divided allelic repeats into 3 subclasses with short, medium, and long (GT)n repeats: short repeats with less than 23 (GT)n were designated as allele class S (short), medium repeats with 23 to 28 (GT)n as allele class M (medium), and long repeats with 29 or more (GT)n as allele class L (long). We had 6 genotypes, S/S, S/M, M/M, S/L, L/M, and L/L, with percentage frequencies (absolute frequencies) of 7.2% (66), 6.9% (63), 3.1% (28), 30.8% (282), 22.7% (208), and 29.4% (269), respectively. The genotypes were categorized into 3 groups: group 1 with S/S genotype, group 2 with S/M and S/L genotypes, and group 3 with M/M, L/M, and L/L genotypes.
###end p 20
###begin title 21
Clinical characteristics
###end title 21
###begin p 22
###xml 117 124 117 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
There were no differences in any of the clinical parameters, including medications, among the three genotype groups (Table 1). Group 1 showed no difference in clinical parameters from either of the other two groups. The bilirubin level was not related to the HO-1 genotypes.
###end p 22
###begin title 23
The HO-1 genotype and renal impairment of IgA nephropathy at the time of renal biopsy
###end title 23
###begin p 24
###xml 158 164 158 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 646 653 646 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Table 2</xref>
###xml 688 696 <span type="species:ncbi:9606">patients</span>
###xml 781 789 <span type="species:ncbi:9606">patients</span>
The prevalence of renal impairment differed among the three genotypic groups. In group 1, the renal impairment rate of 18.2% was lower than 32.2% in group 3 (Fig. 2). The univariate factors related to the renal impairment of IgA nephropathy at the time of renal biopsy were age, diabetes mellitus, hypertension, blood pressures, serum cholesterol, serum uric acid, serum albumin, serum bilirubin, hemoglobin, proteinuria 3+ or more by dipstick urine test, and genotype of the HO-1 gene. In multiple logistic regression analysis adjusted for these factors and gender, the HO-1 genotype was an independent factor for renal impairment at diagnosis (Table 2). The risk of renal impairment in patients with single S allele (group 2) was not significantly different from that of group 3 patients but the odds ratio of renal impairment in group 1 was 0.216-fold lower than that in group 3. The odds ratio of impaired renal function in S/S genotype group was 0.249 compared to the other genotypes (group 2 and group 3) and, in S allele group (group 1 and group 2), was 0.598 compared to the other genotypes (group 3).
###end p 24
###begin title 25
The HO-1 genotype and renal impairment in subgroups stratified by risk factors
###end title 25
###begin p 26
###xml 390 397 390 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">Table 3</xref>
###xml 778 779 778 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 19 27 <span type="species:ncbi:9606">patients</span>
###xml 329 332 <span type="species:ncbi:9606">men</span>
When we stratified patients by gender, age with the criterion of 50 yr, hypertension, and proteinuria 3+ or more by dipstick urine test, which are related to the renal impairment in IgA nephropathy, the rate of renal impairment in group 1 was lower than that in the other groups (group 2 and group 3), especially in subgroups of men, subjects aged 50 yr or more, and normotensive subjects (Table 3). In subjects with proteinuria by dipstick test less than 3+, group 1 tended to have a lower frequency of renal impairment than the other groups, although the difference was not statistically significant. When we stratified the female group by age, the frequency of renal impairment of group 1 was lower than that of the other groups in females aged 50 yr or more (0/3 vs. 44/72, p=0.019).
###end p 26
###begin title 27
The risk factors for mortality in IgA nephropathy
###end title 27
###begin p 28
###xml 124 125 124 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 442 449 442 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T4">Table 4</xref>
###xml 558 559 558 559 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 633 634 633 634 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 702 703 702 703 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 775 776 775 776 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 859 860 859 860 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1008 1009 1008 1009 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1077 1078 1077 1078 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1088 1089 1088 1089 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 34 42 <span type="species:ncbi:9606">patients</span>
###xml 94 102 <span type="species:ncbi:9606">patients</span>
###xml 156 164 <span type="species:ncbi:9606">patients</span>
###xml 464 472 <span type="species:ncbi:9606">patients</span>
###xml 522 530 <span type="species:ncbi:9606">patients</span>
###xml 598 606 <span type="species:ncbi:9606">patients</span>
###xml 664 672 <span type="species:ncbi:9606">patients</span>
###xml 727 735 <span type="species:ncbi:9606">patients</span>
###xml 971 979 <span type="species:ncbi:9606">patients</span>
There were no deaths among the 64 patients of group 1 whereas there were 11 deaths in the 821 patients of the other groups (p>0.05). All deaths occurred in patients with the L allelic group (11/732). The causes of death were renal failure, nephrotic syndrome, sepsis, heart failure, and subdural hemorrhage. Among univariate risk factors related to mortality, diabetes mellitus, eGFR, and body mass index (BMI) were independent risk factors (Table 4). Three of 24 patients with diabetes mellitus died, as did 8 of the 807 patients without diabetes mellitus (p=0.003). There was no mortality in 624 patients with eGFR 60 mL/min/1.73 m2 or more, 6 deaths out of 196 patients with eGFR 30-59 mL/min/1.73 m2, and 5 deaths among 65 patients with eGFR less than 30 mL/min/1.73 m2 (p<0.001). The subgroups with BMI less than 18.5, 18.5-24.9, 25.0-29.9, and 30.0 kg/m2 or more showed mortality rates of 7.5% (3/40), 0.8% (4/474), 1.0% (2/210), and 0.0% (0/23), respectively. The patients with BMI less than 18.5 kg/m2 showed significantly higher mortality than those with BMI 18.5 kg/m2 or more (p=0.011).
###end p 28
###begin title 29
DISCUSSION
###end title 29
###begin p 30
###xml 495 497 495 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 499 501 499 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 503 505 503 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 507 509 507 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 539 541 539 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 549 551 549 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 552 554 552 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 566 568 566 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 570 572 570 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 830 832 830 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 1036 1038 1036 1038 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
In this study, we demonstrated that HO-1 gene promoter polymorphism was related to the prevalence of renal impairment at diagnosis, which is an important risk factor for mortality of IgA nephropathy. HO-1 messenger RNA expression and enzyme activity are greater when the (GT) repeat length in the HO-1 gene promoter region is short but the cut-off point of (GT) repeat number related to HO-1 inducibility repeats of the short allele for HO-1 gene length polymorphism has most commonly been <25 (17, 25, 32, 33), but has also included <28 (24), <27 (21-23), and <23 (19, 20). With the transient-transfection assay with HO-1 gene promoter regions containing various numbers of (GT) repeats, the promoter activity of the HO-1 gene was up-regulated in genes with 16 or 20 (GT) repeats but was not in genes with 29 or 38 (GT) repeats (19). The reporter gene expression driven by the HO-1 gene promoter carrying 22 (GT) repeats was about four- and eight-fold greater than that directed by promoters with 26 and 30 (GT) repeats, respectively (20). Therefore, we grouped the HO-1 gene length polymorphism genotypes into 3 groups with the criteria of less than 23, 23 to 28, and 29 or more (GT) repeats.
###end p 30
###begin p 31
###xml 148 149 148 149 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 482 484 482 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 540 541 540 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 593 601 <span type="species:ncbi:9606">patients</span>
###xml 648 656 <span type="species:ncbi:9606">patients</span>
The short allele of the HO-1 promoter gene was related to the lower rate of renal impairment defined by the estimated GFR less than 60 mL/min/1.73 m2 as calculated with the modified MDRD equation. Although the MDRD equation was not fully verified to estimate kidney function in the Korean population, we believe that our results are acceptable because the risk of renal impairment defined by the calculated creatinine clearance less than 60 mL/min by the Cockcrauft-Gault equation (34) was also 0.073 (95% confidence interval, 0.014-0.378, p=0.002 by multiple logistic regression analysis) in patients with the S/S genotype compared to the risk in patients with the M/M, L/M, or L/L genotype.
###end p 31
###begin p 32
###xml 17 19 17 19 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 135 143 <span type="species:ncbi:9606">patients</span>
###xml 775 782 <span type="species:ncbi:9606">patient</span>
Courtney et al. (25) reported that HO-1 (GT)n promoter polymorphism was not related with the progression to end stage renal disease in patients with IgA nephropathy. In their study, the dependent variable compared between the genotypic groups was the mean age of entry into the renal replacement therapy program. The mean age of entry into this program might be a surrogate marker for renal survival in genetic renal diseases like autosomal dominant polycystic kidney disease but is not usually accepted as a primary outcome in IgA nephropathy. Although the data at the time of renal biopsy might not be the data at the disease onset point, we should consider the clinical status at the time of renal biopsy and adjust the differences of clinical status at diagnosis between patient groups to estimate the risk of disease progression, statistically.
###end p 32
###begin p 33
###xml 227 229 227 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 346 348 346 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 350 352 350 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 368 370 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 748 750 748 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 529 537 <span type="species:ncbi:9606">patients</span>
Although the glomerular injury in IgA nephropathy is usually provoked by IgA-induced mesangial cell activation and complement activation leading to pro-inflammatory and pro-fibrotic phenotype transformation in mesangial cells (26), increased oxidative stress was reported to play some roles in the development and progression of IgA nephropathy (27, 28). Chen et al. (28) observed that the renal infiltration of polymorphonuclear leukocytes, which has a high potential for the production of reactive oxygen species, increased in patients with IgA nephropathy. Advanced oxidation protein products increased in progressed IgA nephropathy compared with in stable IgA nephropathy and was an independent risk factor to renal outcome of IgA nephropathy (27).
###end p 33
###begin p 34
###xml 375 377 375 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
The HO-1 antioxidant effect is mediated by the removal of pro-oxidant heme, generation of biliverdin and bilirubin, coinduction of ferritin, reduction of hydroxyl radical production, and suppression of the pro-oxidant MCP-1 (reviewed in 1). Renal up-regulation of HO-1 attenuates inducible nitric oxide synthase expression and proteinuria in experimental glomerulonephritis (16). For consideration of the pathogenic mechanism of IgA nephropathy and the roles of the HO-1 gene, the relationship between the renal impairment of IgA nephropathy at diagnosis and the inducibility of the HO-1 gene promoter has logical relevance.
###end p 34
###begin p 35
###xml 317 319 317 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
###xml 346 348 346 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B36">36</xref>
###xml 527 529 527 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 511 516 <span type="species:ncbi:9606">women</span>
###xml 597 605 <span type="species:ncbi:9606">patients</span>
The relationship between HO-1 promoter length polymorphism and renal impairment was evident only in males, partially because of the gender-difference of HO-1 inducibility to various stresses. The induction of HO-1 expression and activity was more enhanced in females than in males after trauma and hemorrhagic shock (35) and myocardial ischemia (36). Actually, the S/S genotype was related to a lower rate of renal impairment in females older than 50 yr, which is older than the mean age of menopause in Korean women of 47 yr (37). The HO-1 inducibility was not related to the renal impairment of patients with more severe clinical findings such as hypertension and high proteinuria, suggesting that the influence of the HO-1 gene might be overwhelmed by the clinical risk factors.
###end p 35
###begin p 36
This study had several limitations. The devices for measuring serum creatinine were different among institutions. Jaffe's colorimetric method was used to measure the level of serum creatinine in all of the participating institutions, but the device models differed. We did not standardize the results by calibrating the serum creatinine value of each institution to the result of one standard device. The mortality data were from the national mortality database and we could not assess whether or not the primary cause of mortality was correct.
###end p 36
###begin p 37
In conclusion, the short allele of HO-1 gene promoter length polymorphism was related to the lower rate of renal impairment in IgA nephropathy at diagnosis, which is an important risk factor for the mortality of IgA nephropathy.
###end p 37
###begin title 38
APPENDIX
###end title 38
###begin p 39
Members of The PREMIER group: Institutions that participated in the study (Investigators).
###end p 39
###begin p 40
###xml 1427 1431 <span type="species:ncbi:8839">Duck</span>
Cheju National University Hospital (Eun Hee Jang), Chonbuk National University Medical School (Won Kim), Chonnam National University Medical School (Nam Ho Kim, Woo Kyun Bae), Chungbuk National University College of Medicine (Hye Young Kim), Chungnam National University College of Medicine (Young-Tai Shin, Kang Wook Lee, Ki-Ryang Na), Daegu Catholic University Medical Center (Ki Sung Ahn), Dankook University Hospital (Jong Tae Cho, Eun Kyeong Lee), Dong-A University College of Medicine (Ki Hyun Kim, WonSuk An, Seong Eun Kim), Ewha Womans University School of Medicine (Choi Gyu Bog, Seung-Jung Kim), Gachon University of Medicine and Science (Woo Kyung Chung, Hyun Hee Lee, Jaeseok Yang, Sejoong Kim), Gyeongsang National University Hospital (Se-Ho Chang), Hallym University College of Medicine (Jung Woo Noh, Young Ki Lee, Seong Gyun Kim, Jieun Oh, Young Rim Song), Inha University College of Medicine (Moon Jae Kim, Seoung Woo Lee), Inje University College of Medicine (Yeong Hoon Kim, Won Do Park), Keimyung university school of medicine (Hyun Chul Kim, Sung Bae Park), Konkuk University School of Medicine (Kyo-Soon Kim), Korea University Anam Hospital (Won Yong Cho, Hyoung Kyu Kim, Sang-Kyung Jo), Korea University Ansan Hospital (Cha Dae Ryong, Kang Young Sun), Korea University College of Medicine Guro Hospital (Young-Joo Kwon), Kyungpook National University School of Medicine (Yong-Lim Kim, Sun-Hee Park, Chan-Duck Kim), Pochon CHA University College of Medicine (Dong Ho Yang), Pusan National University School of Medicine (Ihm Soo Kwak, Soo Bong Lee, Dong Won Lee, Sang Heon Song, Eun Young Seoung), Seoul Medical Center (Su-Jin Yoon), Seoul National University Bundang Hospital (Dong-Wan Chae, Ki Young Na, Ho Jun Chin), Seoul National University College of Medicine Boramae Medical Center (Chun Soo Lim, Yoon Kyu Oh), Seoul National University Hospital (Kook Hwan Oh, Kwon Wook Joo, Yon-Su Kim, Curie Ahn, Jin Suk Han, Suhnggwon Kim), Seoul National University Hosptial Clinical Institute (Hyung Jin Yoon), Sungkyunkwan University School of Medicine (Kyu-Beck Lee), Sungkyunkwan University School of Medicine Samsung Medical Center (Yoon Goo Kim, Jung Eun Lee), Ulsan University College of Medicine, Asan Medical Center (Sang Koo Lee), Yeungnam University College of Medicine (Jun-Young Do, Jong-Won Park, Kyung-Woo Yoon), ordered by alphabet.
###end p 40
###begin p 41
###xml 32 92 32 92 <funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Collaborative Research Grant of Korean Society of Nephrology</funding-source>
This study was supported by the Collaborative Research Grant of Korean Society of Nephrology.
###end p 41
###begin article-title 42
Heme oxygenase 1: does it have a role in renal cytoprotection?
###end article-title 42
###begin article-title 43
A beneficial role of bile pigments as an endogenous tissue protector: anti-complement effects of biliverdin and conjugated bilirubin
###end article-title 43
###begin article-title 44
Heme oxygenase modulates selectin expression in different regional vascular beds
###end article-title 44
###begin article-title 45
Carbon monoxide suppresses arteriosclerotic lesions associated with chronic graft rejection and with balloon injury
###end article-title 45
###begin article-title 46
Carbon monoxide protects pancreatic beta-cells from apoptosis and improves islet function/survival after transplantation
###end article-title 46
###begin article-title 47
Carbon monoxide generated by heme oxygenase I suppresses endothelial cell apoptosis
###end article-title 47
###begin article-title 48
Heme: a novel inducer of MCP-1 through HO-dependent and HO-independent mechanisms
###end article-title 48
###begin article-title 49
Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway
###end article-title 49
###begin article-title 50
Cellular overexpression of heme oxygenase-I up-regulates p21 and confers resistance to apoptosis
###end article-title 50
###begin article-title 51
Heme: a determinant of life and death in renal tubular epithelial cells
###end article-title 51
###begin article-title 52
Stress protein induced immunosuppression: Inhibition of cellular immune effector functions following overexpression of haem oxygenase (HSP 32)
###end article-title 52
###begin article-title 53
###xml 85 88 <span type="species:ncbi:10116">rat</span>
Induction of heme oxygenase is a rapid, protective response in rhabdomyolysis in the rat
###end article-title 53
###begin article-title 54
Induction of kidney heme oxygenase-1 (HSP 32) mRNA and protein by ischemia/reperfusion: possible role of heme as both promotor of tissue damage and regulator of HSP32
###end article-title 54
###begin article-title 55
Protective effect of heme oxygenase induction in ischemic acute renal failure
###end article-title 55
###begin article-title 56
Heme oxygenase is induced in nephrotoxic nephritis and hemin, a stimulator of heme oxygenase synthesis, ameliorates disease
###end article-title 56
###begin article-title 57
Heme oxygenase-1 induction attenuates inducible nitric oxide synthase expression and proteinuria in glomerulonephritis
###end article-title 57
###begin article-title 58
Donor heme oxygenase-1 genotype is associated with renal allograft function
###end article-title 58
###begin article-title 59
###xml 55 60 <span type="species:ncbi:9606">human</span>
Oxidative stress causes enhanced endothelial injury in human heme oxygenase-1 deficiency
###end article-title 59
###begin article-title 60
Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema
###end article-title 60
###begin article-title 61
###xml 145 153 <span type="species:ncbi:9606">patients</span>
Microsatellite polymorphism in promoter of heme oxygenase-1 gene is associated with susceptibility to coronary artery disease in type 2 diabetic patients
###end article-title 61
###begin article-title 62
Microsatellite polymorphism in heme oxygenase-1 gene promoter is associated with susceptibility to oxidant-induced apoptosis in lymphoblastoid cell lines
###end article-title 62
###begin article-title 63
###xml 99 107 <span type="species:ncbi:9606">patients</span>
Heme oxygenase-1 gene promoter polymorphism is associated with coronary artery disease in Japanese patients with coronary risk factors
###end article-title 63
###begin article-title 64
Association of susceptibility to the development of lung adenocarcinoma with the heme oxygenase-1 gene promoter polymorphism
###end article-title 64
###begin article-title 65
Fundamental role for HO-1 in the self-protection of renal allografts
###end article-title 65
###begin article-title 66
Association of functional haem oxygenase-1 gene promoter polymorphism with polycystic kidney disease and IgA nephropathy
###end article-title 66
###begin article-title 67
IgA nephropathy
###end article-title 67
###begin article-title 68
Early detection of IgA nephropathy progression: proteinuria and AOPP are strong prognostic markers
###end article-title 68
###begin article-title 69
###xml 62 70 <span type="species:ncbi:9606">patients</span>
Oxidative metabolism of polymorphonuclear leukocytes (PMN) in patients with IgA nephropathy
###end article-title 69
###begin article-title 70
Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)
###end article-title 70
###begin article-title 71
###xml 99 107 <span type="species:ncbi:9606">patients</span>
Heme Oxygenase-1 Gene promoter polymorphism is associated with coronary artery disease in Japanese patients with coronary risk factors
###end article-title 71
###begin article-title 72
Carbon monoxide: a putative neural messenger
###end article-title 72
###begin article-title 73
The effect of a promoter polymorphism in the heme oxygenase-1 gene on the risk of ischaemic cerebrovascular events. The influence of other vascular risk factors
###end article-title 73
###begin article-title 74
Restenosis after percutaneous coronary intervention is associated with the angiotensin-II type-1 receptor 1166A/C polymorphism but not with polymorphisms of angiotensin-converting enzyme, angiotensin-II receptor, angiotensinogen or heme oxygenase-1
###end article-title 74
###begin article-title 75
Prediction of creatinine clearance from serum creatinine
###end article-title 75
###begin article-title 76
Sex differences in hepatic heme oxygenase expression and activity following trauma and hemorrhagic shock
###end article-title 76
###begin article-title 77
Sex-related dimorphic response of HIF-1 alpha expression in myocardial ischemia
###end article-title 77
###begin article-title 78
###xml 62 67 <span type="species:ncbi:9606">Women</span>
Age at menopause and cause-specific mortality in South Korean Women: Kangwha Cohort Study
###end article-title 78
###begin p 79
###xml 61 69 <span type="species:ncbi:9606">patients</span>
Frequency distribution of number of (GT)n repeats in all IgA patients.
###end p 79
###begin p 80
###xml 44 45 44 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Frequency of eGFR less than 60 mL/min/1.73 m2 according to genotypes of the HO-1 promoter region.
###end p 80
###begin p 81
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 50 51 50 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
*, compared between genotype group 1 and group 3; p=0.021.
###end p 81
###begin p 82
###xml 19 27 <span type="species:ncbi:9606">patients</span>
Characteristics of patients with IgA nephropathy
###end p 82
###begin p 83
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
*Allele S, (GT)n repeats less than 23 in HO-1 promoter region; Allele M, (GT)n repeats 23-28 in HO-1 promoter region; Allele L, (GT)n repeats 29 or more in HO-1 promoter region; hematuria, >/=5 RBCs/HPF under light microscopy, proteinuria measured by urine dipstick test; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II type I receptor blocker.
###end p 83
###begin p 84
###xml 90 91 90 91 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Multivariate logistic regression model for the presence of eGFR less than 60 mL/min/1.73 m2 at diagnosis
###end p 84
###begin p 85
Allele S, (GT)n repeats less than 23 in HO-1 promoter region; Allele M, (GT)n repeats 23-28 in HO-1 promoter region; Allele L, (GT)n repeats 29 or more in HO-1 promoter region.
###end p 85
###begin p 86
###xml 105 106 105 106 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Model 1-3: adjusted with gender and univariate factors to the presence of eGFR less than 60 mL/min/1.73 m2, such as age, diabetes mellitus, hypertension, systolic blood pressure, diastolic blood pressure, serum cholesterol, serum uric acid, serum albumin, serum bilirubin, hemoglobin, proteinuria 3+ or more by dipstick test, and genotype of HO-1 promoter region.
###end p 86
###begin p 87
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 50 56 50 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8224;</sup>
###xml 131 144 126 127 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8225;</sup>
*, compared to M/M, L/M, L/L genotypes (group 3); dagger, compared to S/M, S/L, M/M, L/M, and L/L genotypes (group 2 and group 3); double dagger, compared to M/M, L/M, and L/L genotypes (group 3).
###end p 87
###begin p 88
OR, odds ratio; C.I., confidence interval.
###end p 88
###begin p 89
###xml 48 49 48 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
The frequency of eGFR less than 60 mL/min/1.73 m2 of genotypes of the HO-1 promoter region in each subgroup
###end p 89
###begin p 90
###xml 39 47 <span type="species:ncbi:9606">Patients</span>
Number, n (%); Genotype S/S (group 1), Patients who had (GT)n repeats less than 23 in both alleles of HO-1 promoter region.
###end p 90
###begin p 91
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
*, Genotype S/M, S/L, M/M, L/M, L/L (group 2 and group 3).
###end p 91
###begin p 92
The Cox hazard proportional analysis for death in IgA nephropathy
###end p 92
###begin p 93
Model: adjusted with age, gender, diabetes mellitus, hypertension, body mass index, systolic blood pressure, diastolic blood pressure, serum cholesterol, serum albumin, hemoglobin, hematuria, estimated GFR, and genotype of HO-1 promoter region.
###end p 93
###begin p 94
RR, relative risk to death; C.I., confidence interval.
###end p 94

